Oncoc4Incis A Late Stage Biopharmaceutical Company Located In Rockvillemarylandthe Company Focuses On Developing Innovative Medicines For Challenging Cancers And Alzheimer S Diseaseit Utilizes Unique Targets Such As Ctla 4Cd24And Siglecs To Create Safer And More Effective Cancer Therapies Through Advanced Research And Various Therapeutic Approaches The Company S Pipeline Features A Range Of Therapeutic Modalitiesincluding Monoclonal Antibodiesbispecific Antibodiesantibody Drug Conjugatesand Car T Cell Therapiesnotable Candidates Include Gotistobartbnt316 Onc 392 A Next Generation Anti Ctla 4 Antibody Developed With Biontechand Ai 081A Pd 1 Vegf Bispecific Antibodyoncoc4 Has Established Significant Partnershipsincluding A Collaboration With Biontech For The Co Development Of Onc 392And Is Expanding Its Capabilities Through A Merger With Acroimmune In 2024
No conferences found for this company.
| Company Name | Oncoc4 Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
